The AlphaLISA® immunoassay kit for human fatty acid binding protein 3 (FABP3) enables the quantitative determination of human FABP3 in buffer, cell cultrue media, and serum using a homogeneous AlphaLISA assay (no wash steps).
You successfully added item(s) to your cart
For research use only. Not for use in diagnostic procedures.
Please enter valid quantity
Please login to add favorites
NULL OR EMPTY CART
AlphaLISA technology allows the detection of molecules of interest in buffer, cell culture media, serum and plasma in a highly sensitive, quantitative, reproducible and user-friendly mode. In an AlphaLISA assay, a Biotinylated Anti-Analyte Antibody binds to the Streptavidin-coated Alpha Donor beads, while another Anti-Analyte Antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads provokes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.
Fatty Acid-Binding Protein (FABP3) is also known as Heart-type FABP (H-FABP). FABP3 is a low molecular weight (15 kDa) protein located in the cytosol of the myocardium. During myocardial infarction, FABP3 is released into the blood where it circulates. Levels of FABP3 in the blood can be used as a marker for Acute Myocardial Infarction (AMI). Together with Troponin, FABP3 levels can be used to identify acute coronary syndrome in patients exhibiting angina.
|Assay Target Class||Protein|
|Product Brand Name||AlphaLISA|
|Shipping Condition||Blue Ice|
|Unit Size||100 Assay Points|
Too many candidates, too little time. The lack of robust, rapid, high-throughput assays to identify and qualify potential therapeutic targets in areas such as cancer research continues to cost valuable time. What if you could increase assay throughput without compromising sensitivity, obtain more data points from each sample and eliminate tedious wash steps? Find out how AlphaLISA® assay technology, combined with the EnVision® multimode plate reader, provides a fast, powerful, homogeneous platform for screening potential inhibitors of PD-L1 (a protein associated with breast cancer tumor cells) expression in human cells.